我國兒童藥物短缺的現狀分析_《中國循證醫學雜志》

作者：

1. 四川大學華西第二醫院藥學部（成都 610041）；2. 四川大學華西醫院中國循證醫學中心（成都 610041）；3. 四川大學華西藥學院（成都 610041）;

關鍵詞：

兒童藥物短缺現狀分析

DOI：

10.7507/1672-2531.20120181

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

引用本文： 張伶俐,李幼平,胡蝶,曾力楠,梁毅,劉硯韜,代表INDUD. 我國兒童藥物短缺的現狀分析. 中國循證醫學雜志, 2012, 12(10): 1159-1164. doi: 10.7507/1672-2531.20120181 復制

1.	World Health Organization. World Health Statistics 2010 Part Ⅱ. Global Health Indicators. 2010. Available from: http://www.swpho.nhs.uk/resource/item.aspx?RID=78141.
2.	World Health Organization. The global burden of disease 2004 update. 2004. Available from: http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/.
3.	Crowley E, Williams R, Cousins D. Medication errors in children: a descriptive summary of medication error reports submitted to the United States Pharmacopeia. Curr Ther Res, 2001, 62(9): 627-640.
4.	張伶俐, 李幼平, 梁毅. 全球住院兒童超說明書用藥現狀的系統評價. 中國循證醫學雜志, 2012, 12(2): 176-178.
5.	張伶俐, 李幼平, 梁毅. 全球門診兒童超說明書用藥現狀的系統評價. 中國循證醫學雜志, 2012, 12(3): 305-313.
6.	Pandolfini C, Bonati M. A literature review on off-label drug use in children. Eur J Pediatr, 2005, 164(9): 552-558.
7.	曾力楠, 張伶俐. 兒童藥物臨床試驗的發展歷史及研究現狀. 兒童藥學雜志, 2010, 16(2): 4-7.
8.	WHO. 藥物: 兒童藥物. 2010年6月, 實況報道第341號 [2012-02-04]. Available from: http://www.who.int/mediacentre/factsheets/fs341/zh/.
9.	張伶俐, 李幼平, 黃亮. 四川大學華西第二醫院兒科門診處方超藥品說明書用藥情況調查. 中國循證醫學雜志, 2011, 11(10): 1120-1124.
10.	張蘭華, 魏萍. 我國兒科專用藥注冊現狀分析及其對策. 解放軍藥學學報, 2011, 27(2): 178-180.
11.	楊悅, 粟高超. WHO兒童基本藥物示范目錄與我國基本藥物目錄中兒童用藥的比較研究. 中國藥房, 2011, 22(32): 2994-2998.
12.	張伶俐, 張川, 梁毅, 等. 我國2009版基本藥物目錄（基層）與WHO 2010版兒童基本藥物示范目錄比較分析. 中國循證醫學雜志, 2010, 10(9): 1027-1036.
13.	余明蓮, 楊悅. 我國兒童用藥可獲得性的調查分析. 解放軍藥學學報, 2011, 27(4): 368-340.
14.	劉菁, 張艷菊. 北京兒童醫院口服中成藥用法用量分析. 北京中醫藥, 2011, 30(6): 465-466.
15.	谷存芬. 影響兒童用藥的有關因素分析. 臨床和實驗醫學雜志, 2007, 6(11): 158-159.
16.	王麗. 高度關注兒童用藥的安全性. 兒童藥學雜志, 2009, 15(5): 1-4.
17.	WHO/FIP Training Workshop. 兒童處方的制劑研發. Available from: http://apps.who.int/preq ual/006-Pharmacovigilance-Safet_CHN.pdf.
18.	WHO. Development of paediatric medicines: points to consider in pharmaceutical development. Available from: www.who.int/.../expertcommittees/pharmprep/Rev2-PaediatricMedicinesDevelopment_QAS08-257Rev1_8102010.pdf.
19.	Food and Drug Administration. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients. Final Rule:21 CFR Parts 201,312,314,601.Docket No.97N-0165.
20.	Menson EN, Walker AS, Gibb DM. Clinical trials in children. Lancet, 2004, 364(18/25): 2176-2177.
21.	國家發展改革委. 國家發展改革委關于印發《藥品差比價規則》的通知. 發改價格[2011]2452號.
22.	四川省非基層醫療機構藥品采購、配送、監督平臺. Available from: http://fjc.scbid.gov.cn/BidMedicine.aspx.
23.	俞觀文. 對藥品生產成本的思考. 中國制藥信息, 2006, 22(9): 1-3.
24.	FDA. Food and Drug Administration Modernization Act of 1997.Available from: http://www.fda.gov/downloads/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDAMA/FullTextofFDAMAlaw/UCM089145.pdf.
25.	Daniel K, Benjamin JrP, Brian SM, et al. Safety and Transparency of Pediatric Drug Trials. Arch Pediatr Adolesc Med, 2009, 163(12): 1080-1086.
26.	Boot I, Sukhai RN, Klein RH, et al. Stimulation programs for pediatric drug research – do children really benefit? Eur J Pediatr, 2007, 166(18): 849-855.
27.	No anthors listed. Regulations requiring manufactures to assess the safety and effectiveness of new drugs and biological products in pediatric patients. Fed Regist, 1998, 63(231): 66631-66672.
28.	FDA. Best Pharmaceuticals for Children Act. Available from: http://bpca.nichd.nih.gov/collaborativeefforts/initiatives/index.cfm.
29.	FDA. Pediatric Research Equity Act. Available from: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM049870.pdf.
30.	Committee for Proprietary Medicinal Products. Note for guidance on clinical investigation of medicinal products in children. London: European Medicines Agency, 1997.
31.	Editorial. A European Clinical Trials Registry for Children. Paediatric and Perinatal Drug Therapy, 2003, 5(3): 98-100.
32.	Breitkreutz J. European Perspectives on Pediatric Formulations. Clinical Therapeutics, 2008, 30(11): 2146-2154.
33.	European Commission. Paediatric Investigation Plan . Available from: http://www.child-medicines-research-info.com/paediatric-research-consultancy/paediatric-investigation-plans.asp.
34.	European Medicines Agency. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2011/09/WC500112071.pdf.
35.	Choonara I. Regulation of drugs for children in Europe. BMJ, 2007, 335(7632): 1221-1222.
36.	NIH. ClinicalTrials.gov. Available from: http://www.clinicaltrials.gov/ct2/results/map?term=pediatric trials.
37.	FDA. Best Pharmaceuticals for Children Act. Available from: http://bpca.nichd.nih.gov/collaborativeefforts/initiatives/index.cfm.

1. World Health Organization. World Health Statistics 2010 Part Ⅱ. Global Health Indicators. 2010. Available from: http://www.swpho.nhs.uk/resource/item.aspx?RID=78141.
2. World Health Organization. The global burden of disease 2004 update. 2004. Available from: http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/.
3. Crowley E, Williams R, Cousins D. Medication errors in children: a descriptive summary of medication error reports submitted to the United States Pharmacopeia. Curr Ther Res, 2001, 62(9): 627-640.
4. 張伶俐, 李幼平, 梁毅. 全球住院兒童超說明書用藥現狀的系統評價. 中國循證醫學雜志, 2012, 12(2): 176-178.
5. 張伶俐, 李幼平, 梁毅. 全球門診兒童超說明書用藥現狀的系統評價. 中國循證醫學雜志, 2012, 12(3): 305-313.
6. Pandolfini C, Bonati M. A literature review on off-label drug use in children. Eur J Pediatr, 2005, 164(9): 552-558.
7. 曾力楠, 張伶俐. 兒童藥物臨床試驗的發展歷史及研究現狀. 兒童藥學雜志, 2010, 16(2): 4-7.
8. WHO. 藥物: 兒童藥物. 2010年6月, 實況報道第341號 [2012-02-04]. Available from: http://www.who.int/mediacentre/factsheets/fs341/zh/.
9. 張伶俐, 李幼平, 黃亮. 四川大學華西第二醫院兒科門診處方超藥品說明書用藥情況調查. 中國循證醫學雜志, 2011, 11(10): 1120-1124.
10. 張蘭華, 魏萍. 我國兒科專用藥注冊現狀分析及其對策. 解放軍藥學學報, 2011, 27(2): 178-180.
11. 楊悅, 粟高超. WHO兒童基本藥物示范目錄與我國基本藥物目錄中兒童用藥的比較研究. 中國藥房, 2011, 22(32): 2994-2998.
12. 張伶俐, 張川, 梁毅, 等. 我國2009版基本藥物目錄（基層）與WHO 2010版兒童基本藥物示范目錄比較分析. 中國循證醫學雜志, 2010, 10(9): 1027-1036.
13. 余明蓮, 楊悅. 我國兒童用藥可獲得性的調查分析. 解放軍藥學學報, 2011, 27(4): 368-340.
14. 劉菁, 張艷菊. 北京兒童醫院口服中成藥用法用量分析. 北京中醫藥, 2011, 30(6): 465-466.
15. 谷存芬. 影響兒童用藥的有關因素分析. 臨床和實驗醫學雜志, 2007, 6(11): 158-159.
16. 王麗. 高度關注兒童用藥的安全性. 兒童藥學雜志, 2009, 15(5): 1-4.
17. WHO/FIP Training Workshop. 兒童處方的制劑研發. Available from: http://apps.who.int/preq ual/006-Pharmacovigilance-Safet_CHN.pdf.
18. WHO. Development of paediatric medicines: points to consider in pharmaceutical development. Available from: www.who.int/.../expertcommittees/pharmprep/Rev2-PaediatricMedicinesDevelopment_QAS08-257Rev1_8102010.pdf.
19. Food and Drug Administration. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients. Final Rule:21 CFR Parts 201,312,314,601.Docket No.97N-0165.
20. Menson EN, Walker AS, Gibb DM. Clinical trials in children. Lancet, 2004, 364(18/25): 2176-2177.
21. 國家發展改革委. 國家發展改革委關于印發《藥品差比價規則》的通知. 發改價格[2011]2452號.
22. 四川省非基層醫療機構藥品采購、配送、監督平臺. Available from: http://fjc.scbid.gov.cn/BidMedicine.aspx.
23. 俞觀文. 對藥品生產成本的思考. 中國制藥信息, 2006, 22(9): 1-3.
24. FDA. Food and Drug Administration Modernization Act of 1997.Available from: http://www.fda.gov/downloads/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDAMA/FullTextofFDAMAlaw/UCM089145.pdf.
25. Daniel K, Benjamin JrP, Brian SM, et al. Safety and Transparency of Pediatric Drug Trials. Arch Pediatr Adolesc Med, 2009, 163(12): 1080-1086.
26. Boot I, Sukhai RN, Klein RH, et al. Stimulation programs for pediatric drug research – do children really benefit? Eur J Pediatr, 2007, 166(18): 849-855.
27. No anthors listed. Regulations requiring manufactures to assess the safety and effectiveness of new drugs and biological products in pediatric patients. Fed Regist, 1998, 63(231): 66631-66672.
28. FDA. Best Pharmaceuticals for Children Act. Available from: http://bpca.nichd.nih.gov/collaborativeefforts/initiatives/index.cfm.
29. FDA. Pediatric Research Equity Act. Available from: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM049870.pdf.
30. Committee for Proprietary Medicinal Products. Note for guidance on clinical investigation of medicinal products in children. London: European Medicines Agency, 1997.
31. Editorial. A European Clinical Trials Registry for Children. Paediatric and Perinatal Drug Therapy, 2003, 5(3): 98-100.
32. Breitkreutz J. European Perspectives on Pediatric Formulations. Clinical Therapeutics, 2008, 30(11): 2146-2154.
33. European Commission. Paediatric Investigation Plan . Available from: http://www.child-medicines-research-info.com/paediatric-research-consultancy/paediatric-investigation-plans.asp.
34. European Medicines Agency. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2011/09/WC500112071.pdf.
35. Choonara I. Regulation of drugs for children in Europe. BMJ, 2007, 335(7632): 1221-1222.
36. NIH. ClinicalTrials.gov. Available from: http://www.clinicaltrials.gov/ct2/results/map?term=pediatric trials.
37. FDA. Best Pharmaceuticals for Children Act. Available from: http://bpca.nichd.nih.gov/collaborativeefforts/initiatives/index.cfm.

下一篇
適應性設計在藥物研發中的應用現狀及其在中醫藥研究中的應用前景

《中國循證醫學雜志》

我國兒童藥物短缺的現狀分析

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

下一篇

Format

Content

《中國循證醫學雜志》

我國兒童藥物短缺的現狀分析

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

下一篇

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料